SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-026622
Filing Date
2022-12-15
Accepted
2022-12-15 16:52:13
Documents
78
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrv-20220930.htm   iXBRL 10-Q 3234797
2 EX-31.1 acrv-ex31_1.htm EX-31.1 19453
3 EX-31.2 acrv-ex31_2.htm EX-31.2 19434
4 EX-32.1 acrv-ex32_1.htm EX-32.1 13087
5 EX-32.2 acrv-ex32_2.htm EX-32.2 13070
  Complete submission text file 0000950170-22-026622.txt   10338901

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT acrv-20220930_cal.xml EX-101.CAL 44889
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acrv-20220930_lab.xml EX-101.LAB 438655
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT acrv-20220930_def.xml EX-101.DEF 262920
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acrv-20220930.xsd EX-101.SCH 57525
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acrv-20220930_pre.xml EX-101.PRE 385308
72 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20220930_htm.xml XML 1831964
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41551 | Film No.: 221465455
SIC: 2834 Pharmaceutical Preparations